Protease resistant modified erythropoietin polypeptides
View Patent ↗Modified erythropoietin polypeptides that include the mutation R131Q, and uses thereof are provided. Also provided are pharmaceutical compositions, including compositions formulated for oral administration, that contain the modified erythropoietin polypeptides and uses of the compositions to treat diseases and conditions treated by erythropoietin.
1. A modified erythropoietin cytokine, comprising one amino acid replacement in its sequence of amino acid residues, wherein:
the modified erythropoietin cytokine retains an activity of an erythropoietin cytokine, and exhibits increased resistance to proteolysis in serum or blood compared to the unmodified erythropoietin cytokine that does not comprise the amino acid replacement;
the amino acid replacement is R by Q at position 131; and
the R131Q amino acid replacement in the modified erythropoietin cytokine corresponds to an amino acid replacement in a mature erythropoietin cytokine having the sequence set forth in SEQ ID NO: 201.
2. The modified erythropoietin cytokine of claim 1 , wherein the unmodified erythropoietin cytokine comprises a sequence of amino acids set forth in SEQ ID NO: 201.
3. The modified erythropoietin cytokine of claim 1 , wherein the unmodified erythropoietin cytokine has at least 95% sequence identity with an erythropoietin cytokine consisting of a sequence of amino acids set forth in SEQ ID NO, 201.
4. The modified erythropoietin cytokine of claim 1 ,
wherein R131Q is the only amino acid replacement in the modified erythropoietin cytokine.
5. The modified erythropoietin cytokine of claim 1 , wherein only the primary amino acid sequence is modified, and the erythropoietin cytokine exhibits increased resistance to proteolysis.
6. The modified erythropoietin cytokine of claim 1 that exhibits increased stability compared to the unmodified erythropoietin cytokine.
7. The modified erythropoietin cytokine of claim 6 , wherein the erythropoietin cytokine exhibits increased stability to proteases, human blood lysate or human serum.
8. The modified erythropoietin cytokine of claim 1 that exhibits increased protein half-life in vitro or in vivo compared to the unmodified erythropoietin cytokine.
9. The modified erythropoietin cytokine of claim 1 that exhibits increased resistance to proteolysis by a protease of the gastrointestinal tract.
10. The modified erythropoietin cytokine of claim 1 that exhibits increased resistance to proteolysis by a protease in the serum.
11. The modified erythropoietin cytokine of claim 1 , wherein increased resistance to proteolysis is due to the R131Q amino acid replacement that increases resistance of the modified erythropoietin cytokine to digestion by a protease.
12. The modified erythropoietin cytokine of claim 1 , comprising a sequence of amino acids set forth in SEQ ID NO:969.
13. A pharmaceutical composition, comprising a modified erythropoietin cytokine of claim 1 .
14. The pharmaceutical composition of claim 13 , further comprising a pharmaceutically acceptable carrier or excipient.
15. The pharmaceutical composition of claim 14 , wherein the pharmaceutically acceptable carrier or excipient is selected from among a binding agent, a filler, a lubricant, a disintegrant, and a wetting agent.
16. The pharmaceutical composition of claim 13 , further comprising a pharmaceutically acceptable additive.
17. The pharmaceutical composition of claim 16 , wherein the pharmaceutically acceptable additive is selected from among a suspending agent, an emulsifying agent, a non-aqueous vehicle, and a preservative.
18. The pharmaceutical composition of claim 13 , wherein the composition is in the form of a liquid, a solution, a suspension, an aerosol, a tablet, a lozenge or a capsule.
19. The pharmaceutical composition of claim 18 , wherein the composition is in the form of a tablet or a capsule.
20. The pharmaceutical composition of claim 13 , formulated for oral, parenteral, intravenous, intradermal, subcutaneous, buccal, inhalation, intramuscular, rectal or topical administration.
21. The pharmaceutical composition of claim 20 , formulated for oral administration.
22. The pharmaceutical composition of claim 21 , wherein the pharmaceutical composition is formulated for oral administration to the mouth or gastrointestinal tract.
23. The pharmaceutical composition of claim 13 , wherein the pharmaceutical composition is formulated for controlled-release of the modified erythropoietin cytokine.